Expanding JAK Inhibitors to Novel Applications

Publication ID: 24-11857669_0007_PTD
Published: October 28, 2025
Category:New Applications & Use Cases

Legal Citation

pr1or.art Inc., “Expanding JAK Inhibitors to Novel Applications,” Published Technical Disclosure No. 24-11857669_0007_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857669_0007_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,669.

Summary of the Inventive Concept

This inventive concept leverages the core technology of JAK inhibitors to address unmet needs in diverse industries, including aquaculture, livestock, plant health, human exercise performance, and environmental pollution control.

Background and Problem Solved

The original patent focused on treating diseases of the gastrointestinal tract with JAK inhibitors. However, the potential of JAK inhibitors extends beyond this scope. The new inventive concept addresses the limitations of the original patent by exploring novel applications and use cases for JAK inhibitors, thereby unlocking new opportunities for improving health, productivity, and environmental sustainability.

Detailed Description of the Inventive Concept

The new inventive concept involves the use of ingestible devices configured to detect specific targets (e.g., waterborne pathogens, stress in livestock, plant pathogens, muscle fatigue, or environmental pollutants) and release JAK inhibitors to mitigate their effects. This approach enables targeted and controlled delivery of JAK inhibitors, reducing systemic exposure and potential side effects. The ingestible devices can be designed for various formats, such as capsules, tablets, or implants, depending on the specific application and target species.

Novelty and Inventive Step

The new claims introduce a paradigm shift in the use of JAK inhibitors, moving beyond gastrointestinal tract diseases to address unmet needs in distinct industries. The inventive concept's novelty lies in the combination of ingestible devices and JAK inhibitors, which enables targeted delivery and opens up new avenues for improving health, productivity, and environmental sustainability.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include the use of different types of JAK inhibitors, varying release mechanisms, or incorporating additional therapeutic agents. Variations may also involve adapting the ingestible devices for specific species, such as companion animals or fish, or developing implantable devices for long-term release of JAK inhibitors.

Potential Commercial Applications and Market

The new inventive concept has significant commercial potential across multiple industries, including aquaculture, livestock, plant health, human exercise performance, and environmental pollution control. The market opportunities are vast, with potential applications in improving food production, reducing environmental pollutants, and enhancing human health and well-being.

CPC Classifications

SectionClassGroup
A A61 A61K9/0009
A A61 A61K9/0004
A A61 A61K9/0053
A A61 A61K31/519

Original Patent Information

Patent NumberUS 11,857,669
TitleTreatment of a disease of the gastrointestinal tract with a JAK inhibitor and devices
Assignee(s)Biora Therapeutics, Inc.